Zealand Pharma has suffered another setback in its bid to bring glucagon receptor agonist dasiglucagon for ultra-rare disease congenital hyperinsulinism (CHI) to the US market. For the second time ...
those for glucagon autoinjectors increased by 18%, and those for unmixed syringes dipped from 96% to 31%; prefilled syringes and dasiglucagon autoinjectors constituted < 3% of annual glucagon ...
Amphastar's intranasal glucagon dry powder, Baqsimi, and Novo Nordisk’s dasiglucagon auto-injector, Zegalogue, compete with Gvoke. McCulloch said he had yet to see the rivals make a big ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback